IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$4.33

Market cap

$712.78M

P/E Ratio

6.77

Dividend/share

N/A

EPS

$0.64

Enterprise value

$1.09B

?
Relative Growth: Rel. Growth: 80
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 97
Relative Profitability: Rel. Profitability: 94

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the ...

Highlights
The company's equity rose by 35% YoY and by 17% QoQ
IRWD's revenue is up by 22% QoQ and by 14% YoY
The quick ratio has dropped by 55% year-on-year but it has increased by 28% since the previous quarter

Key stats

What are the main financial stats of IRWD

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
5.1%
1 week
12.76%
1 month
32.01%
1 year
485.37%
YTD
28.49%
QTD
2.85%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$361.51M
Gross profit
$361.51M
Operating income
$200.18M
Net income
$102.18M
Gross margin
100%
Net margin
28.3%
The operating income has soared by 103% from the previous quarter
IRWD's operating margin has surged by 66% since the previous quarter
IRWD's revenue is up by 22% QoQ and by 14% YoY
Ironwood Pharmaceuticals's gross profit has increased by 22% QoQ and by 14% YoY

Price vs fundamentals

How does IRWD's price correlate with its fundamentals

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
6.77
P/B
N/A
P/S
1.96
EV/EBIT
5.31
EV/EBITDA
5.22
EV/Sales
3.01
The company's equity rose by 35% YoY and by 17% QoQ
IRWD's P/S is 78% above its last 4 quarters average of 1.1 but 35% below its 5-year quarterly average of 3.0
IRWD's revenue is up by 22% QoQ and by 14% YoY

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's ROIC has soared by 116% from the previous quarter
The return on sales has surged by 64% since the previous quarter

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 33% less than the total liabilities
Ironwood Pharmaceuticals's current ratio has plunged by 58% YoY but it has increased by 25% from the previous quarter
The quick ratio has dropped by 55% year-on-year but it has increased by 28% since the previous quarter
The company's debt to equity has shrunk by 54% YoY and by 21% QoQ
The company's equity rose by 35% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.